Duality Advisers’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-36,365
Closed -$1.01M 396
2024
Q1
$1.01M Buy
+36,365
New +$1.01M 0.1% 324
2023
Q4
Sell
-155,501
Closed -$5.16M 711
2023
Q3
$5.16M Buy
155,501
+22,941
+17% +$811K 0.62% 2
2023
Q2
$4.86M Buy
132,560
+2,588
+2% +$101K 0.61% 2
2023
Q1
$5.3M Buy
+129,972
New +$5.61M 0.6% 11
2022
Q4
Sell
-73,337
Closed -$3.21M 726
2022
Q3
$3.21M Buy
+73,337
New +$3.56M 0.35% 85
2021
Q4
Sell
-133,363
Closed -$5.74M 645
2021
Q3
$5.74M Buy
133,363
+125,391
+1,573% +$5.55M 0.44% 53
2021
Q2
$312K Sell
7,972
-38,524
-83% -$1.5M 0.03% 479
2021
Q1
$1.69M Sell
46,496
-258,833
-85% -$9.19M 0.15% 251
2020
Q4
$11.2M Buy
+305,329
New +$11.2M 0.84% 11
2020
Q3
Sell
-71,700
Closed -$2.22M 635
2020
Q2
$2.22M Buy
+71,700
New +$2.44M 0.2% 139
2020
Q1
Sell
-32,643
Closed -$1.21M 245
2019
Q4
$1.21M Sell
32,643
-65,484
-67% -$2.33M 0.07% 253
2019
Q3
$3.35M Buy
98,127
+85,764
+694% +$3.12M 0.19% 164
2019
Q2
$508K Sell
12,363
-401,163
-97% -$15.9M 0.04% 211
2019
Q1
$16.7M Buy
413,526
+378,217
+1,071% +$15.1M 0.98% 14
2018
Q4
$1.46M Buy
+35,309
New +$1.47M 0.09% 169

Other funds holding PFE

Duality Advisers's PFE Position: Q2 2024 in Review

Duality Advisers sold out of Pfizer (PFE) in Q2 2024, closing a stake of 36,365 shares — an estimated $1.01M sold.

Duality Advisers first reported a position in PFE in Q4 2018 and held it in 15 quarters. The position peaked at $16.7M in Q1 2019. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

  • Duality Advisers reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 36,365 Pfizer shares in Q2 2024, an estimated $1.01M.
  • Duality Advisers first reported a position in Pfizer in Q4 2018 and held it in 15 quarters.
  • Duality Advisers's Pfizer position peaked at $16.7M in Q1 2019.
  • 2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.